|
Orthologous residues
|
|
CdGAP (human): T789‑p, CdGAP (mouse): T776‑p, CdGAP (rat): T779‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], COS (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
monkey, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
GSK3B (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
GSK3A (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
serum starvation
|
|
|
|
increase
|
|
|
NaCl
|
|
|
|
increase
|
|
|
lithium
|
|
|
|
decrease
|
|
|
SB415286
|
|
|
|
decrease
|
|
|
AR-A014418
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
transcription, altered
|
|
Comments:
increases CdGAP expression
|
